

**Johnson & Johnson**

**RECEIVED  
CENTRAL FAX CENTER  
FEB 09 2006**

**CORPORATE HEADQUARTERS  
PATENT LAW DEPARTMENT  
ONE JOHNSON & JOHNSON PLAZA  
NEW BRUNSWICK, NEW JERSEY 08933**

**FACSIMILE TRANSMISSION COVER SHEET**

**TO: USPTO**

**COMPANY:**

**COUNTRY:**

**FACSIMILE NUMBER: 571 273 8300**

**FROM: Peter L. Herridge**

**TELEPHONE NO.: 732 524 5352**

**ROOM NO.:**

**DATE: February 9, 2006**

**FACSIMILE NUMBER: 732 524 2143**

**NUMBER OF PAGES INCLUDING THIS COVER SHEET: 15**

**IF THERE IS A PROBLEM WITH THIS TRANSMISSION, PLEASE CALL**

**COMMENTS: RE: USSN 10/797,795  
Information Disclosure Statement with accompanying documents**

**THIS MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE SOLELY TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.**

Practitioner's Docket No. ORT1575USCNT1

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Carlos R. Plata-Salaman, Boyu Zhao and Roy E. Twyman

Application No.: 10/797,795

Group No.: 4508

Filed: March 10, 2004

Examiner: P.G. Spivack

For: Carbamate compounds for use in preventing or treating neurodegenerative disorders

RECEIVED  
CENTRAL FAX CENTER  
FEB 09 2006Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

## List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)
3. Identification of Person(s) Making This Information Disclosure Statement

## CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10\*

*(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

☐ with sufficient postage as first class mail.

37 C.F.R. § 1.10\*

☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_ (mandatory)

## TRANSMISSION

☒ facsimile transmitted to the Patent and Trademark Office, (571) 273 - 8300.Date: 2/9/06

Signature

Peter L. Herridge

(type or print name of person certifying)

\* Only the date of filing ( ' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" ( ' 1.10) or facsimile transmission ( ' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Information Disclosure Statement--page 1 of 2

© 2006 Matthew Bender &amp; Company, Inc., a member of the LexisNexis Group.

**Section 1. Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


**Section 2. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)**

Form PTO/SB/08A and/or form PTO/SB/08B is/are attached.

**Section 3. Identification of Person Making This Information Disclosure Statement**

The person making this certification is the practitioner who signs below on the basis of the information in the practitioner's file.

Date: 2/9/06

  
Peter L. Herridge  
Registration No. 42,658  
Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
US  
732-524-5352  
Customer No. 000027777

Practitioner's Docket No. ORT1575USCNT1

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Carlos R. Plata-Salaman, Boyu Zhao and Roy E. Twyman

Application No.: 10/797,795

Group No.: 4508

Filed: March 10, 2004

Examiner: P.G. Spivack

For: Carbamate compounds for use in preventing or treating neurodegenerative disorders

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT AFTER  
MAILING DATE OF FINAL ACTION, NOTICE OF ALLOWANCE  
OR ACTION THAT CLOSES PROSECUTION BUT BEFORE  
PAYMENT OF ISSUE FEE (37 C.F.R. § 1.97(d))

---

**CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10\***

(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)


I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. § 1.8(a)**

with sufficient postage as first class mail.

**37 C.F.R. § 1.10\***as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_ (mandatory)**TRANSMISSION**☒ facsimile transmitted to the Patent and Trademark Office, (571) 273 - 8300.Date: 2/9/06  
Signature

Peter L. Heridge

(type or print name of person certifying)

\* Only the date of filing ( ' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" ( ' 1.10) or facsimile transmission ( ' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Transmittal of Information Disclosure Statement After Mailing Date of Final Action, Notice of Allowance or Action that Closes Prosecution But Before Payment of Issue Fee (37 C.F.R. § 1.97(d))--page 1 of 2  
© 2006 Matthew Bender & Company, Inc., a member of the LexisNexis Group.

**TIME OF TRANSMITTAL OF ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed *after* a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

**STATEMENT AND FEE**

2. In accordance with the requirements of 37 C.F.R. § 1.97(d):
- A. Accompanying this transmittal is a statement, as specified in 37 C.F.R. § 1.97(e).
  - B. Applicant submits the fee set forth in § 1.17(p) (\$180.00).

**FEE DUE**

3. Fee due (§ 1.17(p)): \$180.00


**METHOD OF PAYMENT OF FEE**

4. Authorization is hereby made to charge the amount of \$180.00 to Deposit Account No. 10-0750.

Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.

A duplicate of this paper is attached.

Date: 2/9/06

  
Peter L. Herridge  
Registration No. 42,658  
Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
US  
732-524-5352  
Customer No. 000027777

Practitioner's Docket No. ORT1575USCNT1

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Carlos R. Plata-Salaman, Boyu Zhao and Roy E. Twyman

RECEIVED  
CENTRAL FAX CENTER

Application No.: 10/797,795

Group No.: 4508

Filed: March 10, 2004

Examiner: P.G. Spivack

For: Carbamate compounds for use in preventing or treating neurodegenerative disorders

FEB 09 2006

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450STATEMENT FOR INFORMATION DISCLOSURE  
UNDER 37 C.F.R. § 1.97(e)IDENTIFICATION OF INFORMATION DISCLOSURE STATEMENT  
FOR WHICH THIS STATEMENT IS BEING MADE

1. This statement is being made for the Information Disclosure Statement accompanying this statement.

02/10/2006 LWONDIM1 00000066 100750 10797795

01 FC:1806 180.00 DA

---

**CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10\***  
(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. § 1.8(a)**

G with sufficient postage as first class mail.

**37 C.F.R. § 1.10\***

as "Express Mail Post Office to Addressee"

Mailing Label No. \_\_\_\_\_ (mandatory)

**TRANSMISSION**☒ facsimile transmitted to the Patent and Trademark Office, (571) 273 - 0025.Date: 2/9/06Signature Peter L. Herridge  
(type or print name of person certifying)

\* Only the date of filing ( ' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" ( ' 1.10) or facsimile transmission ( ' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

© 2006 Matthew Bender &amp; Company, Inc., a member of the LexisNexis Group. Statement for Information Disclosure Under 37 C.F.R. §§ 1.97(e)—page 1 of 2


**STATEMENT**

2. I, the person signing below, state that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. § 1.97(e)(1).

**IDENTIFICATION OF PERSON MAKING THIS STATEMENT**

3. The person making this certification is the practitioner who signs below on the basis of the information in the practitioner's file.

Date:

2/9/05

Peter L. Herridge  
Registration No. 42,658  
Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
US  
732-524-5352  
Customer No. 000027777

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

7

Attorney Docket Number	ORT1575USCNT1
------------------------	---------------

PAGE 8/15 \* RCVD AT 2/9/2006 3:12:50 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/24 \* DNIS:2738300 \* CSID: \* DURATION (mm:ss):04-04